EUCTR2004-005037-19-IT进行中（未招募）不适用
Multicenter, Double Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies
MSD ITALIA S.R.L.0 个研究点目标入组 200 人开始时间: 2007年8月7日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral TherapiesEUCTR2004-005037-19-DEMerck & Co. Inc.200
进行中（未招募）
1 期
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral Therapiesnspecified human immunodeficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2004-005037-19-DKMerck Sharp & Dohme200
进行中（未招募）
不适用
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral Therapiesnspecified human immunodeficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2004-005037-19-ESMerck & Co. Inc.200
进行中（未招募）
1 期
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of Raltegravir in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral Therapiesnspecified human immunodeficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2004-005037-19-GBMerck Sharp & Dohme Limited
进行中（未招募）
不适用
A multicenter, multiple dose, double-blind, randomized, placebo-controlled, parallel group study of the safety and efficacy of AGN 203818 in female patients with fibromyalgia syndrome.Fibromyalgia syndrome in female patientsMedDRA version: 9.1Level: LLTClassification code 10016631Term: Fibromyalgia syndromeEUCTR2006-006100-11-DEAllergan Ltd160